Publication
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
Journal Paper/Review - Dec 10, 2020
Baird Richard D, Fischer Stefanie, Azaro Analia, Harstrick Andreas, Stumpp Michael T, Leupin Nicolas, Dawson Keith M, Fiedler Ulrike, Zitt Christof, Rodón Jordi, Harris Adrian, Lord Simon, Middleton Mark, Linossi Constanza, Omlin Aurelius